Henry Schein (NASDAQ:HSIC) had its price target raised by Robert W. Baird from $90.00 to $95.00 in a report issued on Thursday, MarketBeat Ratings reports. They currently have an outperform rating on the stock.
HSIC has been the subject of several other research reports. BidaskClub lowered shares of Henry Schein from a buy rating to a hold rating in a report on Thursday, August 30th. ValuEngine raised shares of Henry Schein from a strong sell rating to a sell rating in a report on Thursday, September 13th. Zacks Investment Research raised shares of Henry Schein from a hold rating to a buy rating and set a $85.00 price target for the company in a report on Tuesday, July 10th. Leerink Swann set a $100.00 price target on shares of Henry Schein and gave the company a buy rating in a report on Tuesday, August 7th. Finally, Barrington Research reissued a buy rating and issued a $92.00 price target on shares of Henry Schein in a report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Henry Schein currently has an average rating of Hold and an average price target of $85.06.
Shares of HSIC stock opened at $88.44 on Thursday. Henry Schein has a 12-month low of $62.56 and a 12-month high of $90.52. The firm has a market capitalization of $13.02 billion, a PE ratio of 24.57, a PEG ratio of 2.45 and a beta of 0.97. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.29 and a quick ratio of 0.68.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Monday, August 6th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. Henry Schein had a net margin of 3.15% and a return on equity of 20.40%. The company had revenue of $3.33 billion during the quarter, compared to analyst estimates of $3.31 billion. During the same quarter in the previous year, the business earned $0.88 EPS. The firm’s revenue was up 8.7% on a year-over-year basis. Equities analysts expect that Henry Schein will post 4.12 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CHURCHILL MANAGEMENT Corp bought a new stake in Henry Schein in the 3rd quarter valued at $2,151,000. Jaffetilchin Investment Partners LLC bought a new stake in Henry Schein during the 3rd quarter worth about $338,000. Royal London Asset Management Ltd. bought a new stake in Henry Schein during the 2nd quarter worth about $5,791,000. GHP Investment Advisors Inc. lifted its position in Henry Schein by 9.8% during the 2nd quarter. GHP Investment Advisors Inc. now owns 10,465 shares of the company’s stock worth $760,000 after buying an additional 930 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Henry Schein by 109.3% during the 2nd quarter. Jane Street Group LLC now owns 9,656 shares of the company’s stock worth $701,000 after buying an additional 113,327 shares in the last quarter. 96.65% of the stock is currently owned by institutional investors and hedge funds.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.